Elicio Therapeutics

Historical price data

Elicio Therapeutics' mission is to amplify the immune response against solid tumors by targeting the lymph nodes, the command center of the immune system. Its core achievement is the development of the proprietary Amphiphile (AMP) platform, which leverages albumin shuttling to deliver therapeutic payloads directly to lymph nodes, a strategy designed to generate more potent and coordinated T-cell immunity. The company's strategy is to clinically validate this approach first in high-risk pancreatic cancer with its lead candidate, ELI-002, and subsequently expand the platform to other difficult-to-treat cancers. As a pre-revenue, Nasdaq-listed entity, Elicio is positioned as a pure-play in next-generation, spatially targeted cancer immunotherapies.

The Amphiphile (AMP) platform is a lymph node-targeting technology that conjugates therapeutic payloads (antigens/adjuvants) to a lipid tail, enabling hitchhiking on endogenous albumin for direct delivery to and retention within lymph nodes to amplify immune responses.

Elicio's primary competition comes from other cancer vaccine developers (e.g., BioNTech, Moderna, Gritstone) and KRAS-targeted therapies. Its key differentiator is the lymph node-targeting AMP delivery system, designed to generate a more potent T-cell response, a niche where it has a clinical-stage first-mover advantage.